低剂量糖皮质激素用于重症成人严重肺部感染:综述
本综述汇总低剂量糖皮质激素(定义为每日≤400 mg氢化可的松等效剂量)治疗重症肺部感染的证据。一项6425例COVID-19住院患者的随机临床试验显示地塞米松6 mg/日×10天降低28天死亡率(23% vs 26%)。Meta分析显示该治疗降低重症细菌性社区获得性肺炎30天死亡率(10% vs 16%)、HIV合并中重度肺孢子菌肺炎死亡率(13% vs 25%)及多种原因ARDS住院死亡率(34% vs 45%)。脓毒症休克预设亚组中,社区获得性肺炎患者接受氢化可的松50 mg每6小时静脉+氟氢可的松50 μg/日×7天死亡率低于安慰剂(39% vs 51%)。不良效应包括高血糖、消化道出血、神经精神障碍、肌无力、高钠血症及继发感染。
要点
- 低剂量糖皮质激素定义为每日≤400 mg氢化可的松等效剂量,可降低重症COVID-19、重症社区获得性细菌性肺炎及HIV合并中重度肺孢子菌肺炎患者死亡率。
- COVID-19住院需补氧或无创/有创机械通气患者:地塞米松6 mg/日×10天,28天死亡率23% vs 26%。
- ICU重症细菌性社区获得性肺炎:氢化可的松等效≤400 mg/日×≤8天,30天死亡率10% vs 16%。
- HIV合并中重度肺孢子菌肺炎:低剂量糖皮质激素死亡率13% vs 25%。
- 脓毒症休克合并社区获得性肺炎预设亚组:氢化可的松50 mg每6小时静脉+氟氢可的松50 μg/日×7天,死亡率39% vs 51%。
适用人群与场景
- 重症COVID-19需补氧或无创或有创机械通气的住院成人。
- ICU治疗的严重细菌性社区获得性肺炎成人。
- HIV合并中重度肺孢子菌肺炎患者。
- 脓毒症休克合并社区获得性肺炎的成人(预设亚组)。
- 多种原因所致急性呼吸窘迫综合征成人。
诊断标准与关键阈值
- 低剂量糖皮质激素定义为每日≤400 mg氢化可的松等效剂量。
处置流程与药物剂量
- 重症COVID-19需补氧或无创/有创机械通气:地塞米松6 mg每日一次,疗程10天。
- ICU重症细菌性社区获得性肺炎:氢化可的松等效≤400 mg/日,疗程≤8天。
- 脓毒症休克合并社区获得性肺炎:氢化可的松50 mg每6小时静脉给药+氟氢可的松50 μg每日一次,疗程7天。
研究设计与关键结果
- 6425例COVID-19住院需补氧或无创/有创机械通气患者的随机临床试验:地塞米松6 mg/日×10天组28天死亡率23% vs 26%。
- 纳入7项随机临床试验、1689例ICU重症细菌性社区获得性肺炎患者的Meta分析:氢化可的松等效≤400 mg/日×≤8天组30天死亡率10% vs 16%。
- 纳入6项随机临床试验的Meta分析:HIV合并中重度肺孢子菌肺炎患者低剂量糖皮质激素组死亡率13% vs 25%。
- 脓毒症休克低剂量激素治疗试验的预设亚组分析:社区获得性肺炎患者随机接受氢化可的松50 mg每6小时静脉+氟氢可的松50 μg/日×7天组死亡率39% vs 51%。
- 纳入8项研究、1091例多种原因ARDS患者的Meta分析:低剂量糖皮质激素组住院死亡率34% vs 45%。
- 低剂量糖皮质激素的不良效应可能包括高血糖、消化道出血、神经精神障碍、肌无力、高钠血症和继发感染。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对重症COVID-19需补氧或无创/有创机械通气患者,可依据随机临床试验结果使用地塞米松6 mg/日×10天以降低28天死亡率。
- 对ICU重症细菌性社区获得性肺炎患者,可依据Meta分析结果使用氢化可的松等效≤400 mg/日×≤8天以降低30天死亡率。
- 对HIV合并中重度肺孢子菌肺炎患者,可依据Meta分析结果使用低剂量糖皮质激素以降低死亡率。
- 对脓毒症休克合并社区获得性肺炎患者,可依据预设亚组分析结果使用氢化可的松50 mg每6小时静脉+氟氢可的松50 μg/日×7天。
- 使用低剂量糖皮质激素时需监测高血糖、消化道出血、神经精神障碍、肌无力、高钠血症和继发感染等不良效应。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Severe pulmonary infections, including COVID-19, community-acquired pneumonia, influenza, and Pneumocystis pneumonia, are a leading cause of death among adults worldwide. Pulmonary infections in critically ill patients may cause septic shock, acute respiratory distress syndrome, or both, which are associated with mortality rates ranging between 30% and 50%.
OBSERVATIONS: Corticosteroids mitigate the immune response to infection and improve outcomes for patients with several types of severe pulmonary infections. Low-dose corticosteroids, defined as less than or equal to 400 mg hydrocortisone equivalent daily, can reduce mortality of patients with severe COVID-19, community-acquired pneumonia, and Pneumocystis pneumonia. A randomized clinical trial of 6425 patients hospitalized with COVID-19 who required supplemental oxygen or noninvasive or invasive mechanical ventilation reported that dexamethasone 6 mg daily for 10 days decreased 28-day mortality (23% vs 26%). A meta-analysis that included 7 randomized clinical trials of 1689 patients treated in the intensive care unit for severe bacterial community-acquired pneumonia reported that hydrocortisone equivalent less than or equal to 400 mg daily for 8 days or fewer was associated with lower 30-day mortality compared with placebo (10% vs 16%). In a meta-analysis of 6 randomized clinical trials, low-dose corticosteroids were associated with lower mortality rates compared with placebo for patients with HIV and moderate to severe Pneumocystis pneumonia (13% vs 25%). In a predefined subgroup analysis of a trial of low-dose steroid treatment for septic shock, patients with community-acquired pneumonia randomized to 7 days of intravenous hydrocortisone 50 mg every 6 hours and fludrocortisone 50 μg daily had decreased mortality compared with the placebo group (39% vs 51%). For patients with acute respiratory distress syndrome caused by various conditions, low-dose corticosteroids were associated with decreased in-hospital mortality (34% vs 45%) according to a meta-analysis of 8 studies that included 1091 patients. Adverse effects of low-dose corticosteroids may include hyperglycemia, gastrointestinal bleeding, neuropsychiatric disorders, muscle weakness, hypernatremia, and secondary infections.
CONCLUSIONS AND RELEVANCE: Treatment with low-dose corticosteroids is associated with decreased mortality for patients with severe COVID-19 infection, severe community-acquired bacterial pneumonia, and moderate to severe Pneumocystis pneumonia (for patients with HIV). Low-dose corticosteroids may also benefit critically ill patients with respiratory infections who have septic shock, acute respiratory distress syndrome, or both.
参考来源
- Pirracchio R, Venkatesh B, Legrand M, et al. Low-Dose Corticosteroids for Critically Ill Adults With Severe Pulmonary Infections: A Review. JAMA. 2024. PMID: 38865154. doi:10.1001/jama.2024.6096
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。